Trial · NCT07906886
Topical Terbinafine Versus Hydrocortisone Combined With Oral Itraconazole for Seborrheic Dermatitis
NCT07906886, Phase 4, Completed, Can Tho University of Medicine and Pharmacy
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Terbinafine Versus Hydrocortisone Combined With Oral Itraconazole for Seborrheic Dermatitis. Trials, record NCT07906886. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906886
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Terbinafine Versus Hydrocortisone Combined With Oral Itraconazole for Seborrheic Dermatitis
- NCT number
- NCT07906886
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 76 participants, actual
- Lead sponsor
- Can Tho University of Medicine and Pharmacy
- Conditions
- Seborrheic Dermatitis
- Interventions
- Itraconazole, Terbinafine 1% cream, Hydrocortisone 1% cream
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seborrheic Dermatitis Area and Severity Index (SDASI) score | Week 2 (end of oral itraconazole) | Three-component SDASI (erythema, scaling and itching, each graded 0-3), weighted by area; range 0-12.6, higher scores indicate more severe disease. Scored by a single trained investigator before checking group assignment. |
| Secondary | SDASI score at end of topical treatment | Week 4 | Three-component SDASI (range 0-12.6); higher scores indicate more severe disease. |
| Secondary | Proportion of patients with ≥50% reduction in SDASI from baseline | Week 2 and week 4 | Number of patients achieving at least a 50% reduction in SDASI score compared with baseline. |
| Secondary | Clinical response category | Week 2 and week 4 | Complete clearance (SDASI = 0); marked improvement (≥50% reduction); slight improvement (1-49% reduction); no improvement (no reduction or worsening). |
| Secondary | Itching score | Baseline, week 2 and week 4 | Patient-rated global itching on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). |
| Secondary | Burning score | Baseline, week 2 and week 4 | Patient-rated global burning on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). |
| Secondary | Number of patients with local adverse events at the application site | Week 2 and week 4 | Erythema, itching, rash or swelling/pain at the application site, recorded on a checklist at each follow-up visit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906886
GET https://conductscience.org/api/trials/v1/NCT07906886/registered